Increased Level of Tim-3[+]PD-1[+]CD4[+]T Cells With Altered Function Might Be Associated With Lower Extremity Arteriosclerosis Obliterans.

Autores
Categoría Estudio primario
RevistaFrontiers in immunology
Año 2022

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Lower extremity arteriosclerosis obliterans (LEASO) is a vascular disease that may result in adult limb loss worldwide. CD4[+]T cell-mediated immunity plays a significant role in LEASO. The T cell immunoglobulin and mucin domain 3 (Tim-3) and inhibitory receptor programmed cell death-1 (PD-1) are well-known immune checkpoints that play crucial roles in regulating CD4[+]T cell activation or tolerance. In this study, blood mononuclear cells were isolated from the blood samples of healthy controls and patients who were diagnosed with LEASO for the first time [stage III or IV according to the Fontaine classification system and had not received drugs (except for heparin) or surgery treatment]. We concluded the higher proportion of Tim-3[+]PD-1[+]CD4[+]T cells in human higher stage LEASO, and oxidized low-density lipoprotein increased Tim-3 and PD-1 co-expression by activating CD4[+]T cells in a dose- dependent manner. Tim-3[+]PD-1[+]CD4[+]T cells displayed a more active status and produced more anti-atherogenic cytokines compared to Tim-3[-]PD-1[-]CD4[+]T cells. Apart from the increased frequency, the altered function of Tim-3[+]PD-1[+]CD4[+]T cells was also observed in LEASO compared to those from healthy controls. These in vitro results indicated that Tim-3 and PD-1 might be promising early warning targets of higher stage LEASO. In addition, the blockade of Tim-3 and PD-1 signaling pathways aggravated the pro-atherogenic Th1 responses in LEASO, further suggesting that the cardiovascular safety must be a criterion considered in using immune checkpoint inhibitors to reverse T cell exhaustion during tumors and chronic viral infections.
Epistemonikos ID: 6b688d2c1eed69f20a6ec28c01464dd4ab4bd408
First added on: Nov 09, 2024